The Centre for Inflammation Research at the University of Edinburgh, Queen's Medical Research Institute, Edinburgh BioQuarter, Edinburgh EH16 4TJ, UK.
Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK.
QJM. 2022 May 10;115(5):292-297. doi: 10.1093/qjmed/hcab129.
Immunoglobulin G (IgG) subclass 2 deficiency is the most frequent IgG subclass deficiency identified in patients with bronchiectasis, but its clinical significance is not known.
To analyse if bronchiectasis patients with isolated IgG2 deficiency at risk of recurrent exacerbations and/or hospitalization? Do patients with IgG2 deficiency have worse disease progression?
This is a retrospective study (2015-20) exploring independent risk factors for recurrent exacerbations (3 or more per year) and/or hospitalization with bronchiectasis exacerbations using multivariable models using binary logistic regression. There was no patient with IgG deficiency, IgG 1, 3 or 4 deficiency, or IgA or IgM deficiency included. In this model, the authors included: serum IgG2 level; lung function; body mass index; MRC breathlessness scale; age; sex; number of bronchiectatic lobes; bacterial colonization; comorbidities; and the use of long-term immunosuppressant drugs or antibiotics for more than 28 days. Analysing 2-year longitudinal data, one-way ANOVA and Mann-Whitney U-test were used to compare bronchiectasis severity between patients with different IgG2 levels.
Serum IgG2 levels (<2.68 g/l, 2.68-3.53 g/l and 3.54-4.45 g/l); hospital admission in the preceding 2 years; bacterial colonization with potentially pathogenic organisms and asthma were independent predictors for three or more bronchiectasis exacerbations. Those with low IgG2 levels (<2.68 g/l and 2.68-3.53 g/l), had worsening progression of their bronchiectasis, using the Bronchiectasis Severity Index, over 1 year compared with those who were IgG2 replete (>4.45 g/l) (P = 0.003, 0.013).
Reduced IgG2 levels were an independent predictor for bronchiectasis exacerbations and have increased disease progression.
免疫球蛋白 G(IgG)亚类 2 缺乏症是支气管扩张症患者中最常见的 IgG 亚类缺乏症,但目前尚不清楚其临床意义。
分析支气管扩张症患者中孤立性 IgG2 缺乏症是否有复发性加重和/或住院的风险?IgG2 缺乏症患者的疾病进展是否更差?
这是一项回顾性研究(2015-20 年),使用二元逻辑回归多变量模型探索复发性加重(每年 3 次或以上)和/或支气管扩张症加重住院的独立危险因素。没有包括 IgG 缺乏症、IgG1、3 或 4 缺乏症、IgA 或 IgM 缺乏症的患者。在该模型中,作者纳入了血清 IgG2 水平;肺功能;体重指数;MRC 呼吸困难量表;年龄;性别;支气管扩张肺叶数;细菌定植;合并症;以及长期使用免疫抑制剂或抗生素超过 28 天。分析 2 年的纵向数据,使用单向方差分析和曼-惠特尼 U 检验比较不同 IgG2 水平患者的支气管扩张症严重程度。
血清 IgG2 水平(<2.68 g/l、2.68-3.53 g/l 和 3.54-4.45 g/l);前 2 年住院;潜在致病性细菌定植和哮喘是 3 次或以上支气管扩张症加重的独立预测因子。与 IgG2 充足(>4.45 g/l)的患者相比,低 IgG2 水平(<2.68 g/l 和 2.68-3.53 g/l)的患者在 1 年内支气管扩张症严重程度恶化(P=0.003,0.013)。
低 IgG2 水平是支气管扩张症加重的独立预测因子,且会增加疾病进展。